BiomX Inc. (PHGE) closed a $3 million private placement on December 29 2025, issuing Series Y convertible preferred stock and accompanying warrants that can be exercised for up to 3.3 million common shares. The transaction is expected to close on or about December 30 2025, subject to customary closing conditions.
The infusion of capital is intended to extend BiomX’s cash runway, which stood at $8.1 million as of September 30 2025 and was projected to support operations into the first quarter of 2026. The company will use the proceeds to evaluate opportunities across its phage‑therapy pipeline, with a particular focus on the BX011 program for diabetic foot infections, and for general corporate purposes to maintain operational flexibility while exploring strategic alternatives.
BX011, a phage cocktail targeting Staphylococcus aureus, has received positive feedback from the FDA regarding its clinical development pathway. The program is a key driver of BiomX’s future revenue potential, and the new funding will help sustain its clinical milestones and keep the company in a position to negotiate partnerships or a potential acquisition.
The financing follows a 1‑for‑19 reverse stock split effective November 25 2025, which was undertaken to meet exchange listing requirements. The reverse split, combined with the new capital, positions BiomX to better manage its share count and improve liquidity for future financing rounds.
Management emphasized that the private placement is a strategic move to preserve the company’s ability to pursue its pipeline and to keep options open for a potential merger or acquisition. CEO Jonathan Solomon noted that the company remains focused on advancing its clinical programs while maintaining a disciplined approach to cash burn.
The transaction underscores the ongoing challenge of sustaining a pre‑revenue biotech’s cash position, but it also provides a buffer that allows BiomX to continue its research and development activities without immediate pressure to raise additional capital.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.